Research progress of the relationship between adverse reaction, single nucleotide polymorphism and plasma concentration in renal carcinoma patients treated with sunitinib
10.13699/j.cnki.1001-6821.2016.13.026
- VernacularTitle:舒尼替尼在治疗肾癌的不良反应及其单核苷酸多态性与血药浓度的相关性研究现状
- Author:
Yuan-Yuan ZHANG
1
;
Guo-Fang BI
;
Ze-Yuan LIU
;
Heng-Yan QU
Author Information
1. 军事医学科学院 附属医院 临床药理室
- Keywords:
renal carcinoma;
sunitinib;
single nucleotide polymor-phism;
adverse reaction;
plasma concentration
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(13):1240-1243
- CountryChina
- Language:Chinese
-
Abstract:
There are definite effects of sunitinib molecular target therapy on renal carcinoma , but not all the patients diagnosed with renal carcino-ma could benefit from it.Single nucleotide polymorphism ( SNP ) could be related to point mutations of patients who couldn ’ t bear the toxicity that induced by sunitinib.Besides, the sunitinib induced toxicity could be influenced by the exposure of sunitinib in patient plasma .Therefore the aim of this article was to conduct a systematic review to the relation-ship among adverse reaction , SNPs and plasma concentration in renal carcinoma patients treated with sunitinib .
